Even if a buyout is not coming, there are some other nice catalysts coming in the near term.
1. DEA schedules Belviq; and so ARNA can start selling in the US.
I expect this before the end of October.
2. European approval of Belviq. I expect this by mid-November.
3. European rejection of qsymia. Expected in October. This is much better than a 50/50 possibility because phentermine is banned in europe and phentermine is one of the two components in qsymia. I think that VVUS filed for european approval more as a market-oriented PR stunt than as a serious effort to obtain approval (VVUS management is - IMO - overly concened about the day-to-day movement of its PPS). Why do you think VVUS voluntarily delayed by 3 months its hearing at the EMA (from June to September)? IMO they did not want a european disapproval raining on their FDA process or their insider selling.
4. Announcement of a European partner for marketing Belviq. Could happen anytime.